OPNT News and Press, Opiant Pharmaceuticals Inc. From 03/21/19

Opiant Pharmaceuticals, Inc. (OPNT) Q4 2018 Results Conference Call March 21, 2019 04:30 PM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Dr. Roger Crystal - CEO David O'Toole - CFO Conference Call Participants David Bautz - Zacks Investment Research Prese...

Opiant Pharmaceuticals (NASDAQ: OPNT ): Q4 GAAP EPS of -$0.37 misses by $0.24 . Revenue of $4.76M (-59.5% Y/Y) misses by $0.39M . Press Release More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

SANTA MONICA, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the quarter and year ended December 3...

SANTA MONICA, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the year ended December 31...

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, ...

The broad market's down day notwithstanding, opioid drugmakers are under modest pressure in apparent response to a report that privately held Purdue Pharma is mulling a Chapter 11 bankruptcy filing to protect itself from the ~2,000 lawsuits against it related to its marketing practices for...

-Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus remains on advancing lead product candidate, OPNT003, for treatment of opioid overdose, and other promising addiction and drug overdose-related product cand...